Sonoma Pharmaceuticals, Inc. (SNOA)
NASDAQ: SNOA · IEX Real-Time Price · USD
0.152
-0.007 (-4.34%)
At close: May 1, 2024, 12:24 PM
0.153
+0.001 (0.92%)
After-hours: May 1, 2024, 6:18 PM EDT
Sonoma Pharmaceuticals Revenue
Sonoma Pharmaceuticals had revenue of $12.31M in the twelve months ending December 31, 2023, down -1.96% year-over-year. Revenue in the quarter ending December 31, 2023 was $3.14M with 6.59% year-over-year growth. In the fiscal year ending March 31, 2023, Sonoma Pharmaceuticals had annual revenue of $13.27M with 5.10% growth.
Revenue (ttm)
$12.31M
Revenue Growth
-1.96%
P/S Ratio
0.19
Revenue / Employee
$1,367,778
Employees
9
Market Cap
2.39M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2023 | 13.27M | 644.00K | 5.10% |
Mar 31, 2022 | 12.63M | -6.00M | -32.21% |
Mar 31, 2021 | 18.63M | 701.00K | 3.91% |
Mar 31, 2020 | 17.93M | -1.04M | -5.49% |
Mar 31, 2019 | 18.97M | 2.31M | 13.88% |
Mar 31, 2018 | 16.66M | 3.83M | 29.89% |
Mar 31, 2017 | 12.83M | 3.46M | 36.89% |
Mar 31, 2016 | 9.37M | -4.49M | -32.37% |
Mar 31, 2015 | 13.85M | 186.00K | 1.36% |
Mar 31, 2014 | 13.67M | -1.78M | -11.55% |
Mar 31, 2013 | 15.45M | 2.71M | 21.25% |
Mar 31, 2012 | 12.74M | 2.99M | 30.65% |
Mar 31, 2011 | 9.75M | 2.39M | 32.46% |
Mar 31, 2010 | 7.36M | 1.98M | 36.67% |
Mar 31, 2009 | 5.39M | 1.55M | 40.50% |
Mar 31, 2008 | 3.84M | -708.00K | -15.58% |
Mar 31, 2007 | 4.54M | 1.96M | 75.81% |
Mar 31, 2006 | 2.58M | 1.23M | 90.56% |
Mar 31, 2005 | 1.36M | 454.00K | 50.33% |
Mar 31, 2004 | 902.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSNOA News
- 22 days ago - Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States - Accesswire
- 27 days ago - Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections - Accesswire
- 4 weeks ago - Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences - Accesswire
- 5 weeks ago - Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals - Accesswire
- 2 months ago - Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results - Accesswire
- 3 months ago - Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use - Accesswire
- 4 months ago - NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma's Extensive Distributor Network - Business Wire
- 6 months ago - Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results - Accesswire